AxoGen, Inc.

AxoGen, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. AxoGen, Inc. has good growth characteristics. AxoGen, Inc. is a good stock to invest in, but there are better stocks to choose.

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It a...

News

AxoGen (NASDAQ:AXGN) Stock Rating Lowered by StockNews.com

Zolmax AxoGen (NASDAQ:AXGN - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday.\nSeveral other research firms have also...\n more…

AxoGen (NASDAQ:AXGN) Stock Rating Lowered by StockNews.com

Ticker Report AxoGen (NASDAQ:AXGN - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday. Several other research firms have also...\n more…

Koss Olinger Consulting LLC Invests $75,000 in AxoGen, Inc. (NASDAQ:AXGN)

Ticker Report Koss Olinger Consulting LLC purchased a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional...\n more…

AxoGen (NASDAQ:AXGN) Hits New 1-Year High at $13.35

Ticker Report AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) hit a new 52-week high during trading on Friday . The company traded as high as $13.35 and last traded at $13.21, with a volume of 46307 shares trading...\n more…

Axogen completes marketing submission for Avance Nerve Graft

Seeking Alpha - Healthcare Axogen completes marketing submission for Avance Nerve Graft...\n more…

AxoGen completes submission of BLA to U.S. FDA for Avance Nerve Graft

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…